Clinical Trials Browser

Burkitt Lymphoma, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00084565 2013-07-10

Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer

Phase 2 Withdrawn

Genitourinary

Prostatic Neoplasms

NCT00014352 2013-01-16

Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer

Phase 2 Completed

Genitourinary

Prostatic Neoplasms, Thromboembolism

NCT00003084 2012-07-30

Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer

Phase 2 Completed

75 enrolled

Genitourinary

Prostatic Neoplasms

NCT00193271 2011-05-03

Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer

Phase 2 Completed

30 enrolled

Genitourinary

Prostatic Neoplasms

NCT00193193 2010-08-04

Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma

Phase 2 Completed

100 enrolled

Genitourinary

Prostatic Neoplasms

NCT00176527 2009-12-11

Isotretinoin, Interferon Alfa-2b, Docetaxel, and Estramustine in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Phase 2 Terminated

40 enrolled

Genitourinary

Prostatic Neoplasms

NCT00541281 2009-10-27

Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer

Phase 2 Completed

150 enrolled

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Clinical Trials

EFESE

BEST

Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer

Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer

Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment

Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy

Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer

Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Combination Chemotherapy With or Without Prednisone in Treating Patients With Recurrent and/or Metastatic Kidney Cancer

Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate

Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate

Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy.

Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer

Paclitaxel and Estramustine in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer

Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer

Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer

Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer

Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma

Isotretinoin, Interferon Alfa-2b, Docetaxel, and Estramustine in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer